Fig. 2

AMPK activity in response to Kv1.3 inhibitors in ex vivo skeletal muscle, C₂C₁₂ and L6 myotubes. a Effect of Kv1.3 inhibitors [Pap1 (10 nM), Psora4 (2.5 nM) and MgTx (1 nM) for 1 h] on AMPK activity in differentiated C₂C₁₂ myotubes. b, c Effects of Kv1.3 inhibitors on SOL (b) and EDL (c) AMPK activity. d Effect of Kv1.3 inhibitors on AMPK activity in differentiated L6 myotubes. **P < 0.01, ***P < 0.001, compared with control